These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 37119212)

  • 1. Dexmedetomidine Sublingual Film: A New Treatment to Reduce Agitation in Schizophrenia and Bipolar Disorders.
    Karlin DM; Nelson LA; Campbell AR
    Ann Pharmacother; 2024 Jan; 58(1):54-64. PubMed ID: 37119212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial.
    Preskorn SH; Zeller S; Citrome L; Finman J; Goldberg JF; Fava M; Kakar R; De Vivo M; Yocca FD; Risinger R
    JAMA; 2022 Feb; 327(8):727-736. PubMed ID: 35191924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed.
    Citrome L; Risinger R; Rajachandran L; Robison H
    Adv Ther; 2022 Oct; 39(10):4821-4835. PubMed ID: 36002761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sublingual dexmedetomidine: repurposing an anesthetic as an anti-agitation agent.
    Faden J; Musselman M; Citrome L
    Expert Rev Neurother; 2023 Feb; 23(2):97-106. PubMed ID: 36707066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial.
    Citrome L; Preskorn SH; Lauriello J; Krystal JH; Kakar R; Finman J; De Vivo M; Yocca FD; Risinger R; Rajachandran L
    J Clin Psychiatry; 2022 Oct; 83(6):. PubMed ID: 36198061
    [No Abstract]   [Full Text] [Related]  

  • 6. Dexmedetomidine sublingual film (Igalmi) for acute agitation.
    Med Lett Drugs Ther; 2022 Dec; 64(1666):203-205. PubMed ID: 36542347
    [No Abstract]   [Full Text] [Related]  

  • 7. Sublingual Dexmedetomidine for the Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder.
    Smith CM; Santalucia M; Bunn H; Muzyk A
    Clin Psychopharmacol Neurosci; 2023 May; 21(2):215-221. PubMed ID: 37119214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The treatment of acute agitation associated with schizophrenia or bipolar disorder: investigational drugs in early stages of their clinical development, and their clinical context and potential place in therapy.
    Ward K; Citrome L
    Expert Opin Investig Drugs; 2020 Mar; 29(3):245-257. PubMed ID: 32031021
    [No Abstract]   [Full Text] [Related]  

  • 9. Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder.
    Citrome L
    Int J Clin Pract; 2011 Mar; 65(3):330-40. PubMed ID: 21199198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Agitation in Individuals With Bipolar Disorder or Schizophrenia: Lessons Learned for Clinical Psychiatry and Psychiatric Drug Development.
    Preskorn SH
    J Psychiatr Pract; 2022 Jul; 28(4):319-323. PubMed ID: 35797688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the pharmacotherapeutic treatment of agitation associated with bipolar disorder.
    Faden J; Goldberg JF; Citrome L
    Expert Opin Pharmacother; 2023; 24(16):1811-1822. PubMed ID: 37581475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sublingual Dexmedetomidine vs Placebo and Acute Agitation Associated With Bipolar Disorder.
    Henry PH; Dantz B
    JAMA; 2022 Jul; 328(2):213-214. PubMed ID: 35819431
    [No Abstract]   [Full Text] [Related]  

  • 14. Sublingual Dexmedetomidine vs Placebo and Acute Agitation Associated With Bipolar Disorder.
    Abe A; Takeda Y; Ishiki H
    JAMA; 2022 Jul; 328(2):213. PubMed ID: 35819432
    [No Abstract]   [Full Text] [Related]  

  • 15. Sublingual Dexmedetomidine vs Placebo and Acute Agitation Associated With Bipolar Disorder-Reply.
    Preskorn SH; Risinger R; Kakar R
    JAMA; 2022 Jul; 328(2):214-215. PubMed ID: 35819427
    [No Abstract]   [Full Text] [Related]  

  • 16. Rationale and design of the PLACID study: a randomised trial comparing the efficacy and safety of inhaled loxapine versus IM aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder.
    San L; Estrada G; Oudovenko N; Vieta E
    BMC Psychiatry; 2017 Apr; 17(1):126. PubMed ID: 28376877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.
    Citrome L
    Int J Clin Pract; 2012 Mar; 66(3):318-25. PubMed ID: 22226343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy review of inhaled loxapine for treatment of agitation.
    Currier G; Walsh P
    Clin Schizophr Relat Psychoses; 2013 Apr; 7(1):25-32. PubMed ID: 23538290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia.
    Keating GM
    CNS Drugs; 2013 Jun; 27(6):479-89. PubMed ID: 23740380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New formulations of olanzapine in the treatment of acute agitation].
    Bartkó G
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):171-8. PubMed ID: 17211052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.